Daily Stock Analysis, CURO, NEURALSTEM INC, priceseries

NEURALSTEM INC. Daily Stock Analysis
Stock Information
Open
15.31
Close
15.39
High
15.39
Low
15.03
Previous Close
15.18
Daily Price Gain
0.21
YTD High
15.39
YTD High Date
Sep 11, 2019
YTD Low
9.04
YTD Low Date
Jan 2, 2019
YTD Price Change
5.62
YTD Gain
57.52%
52 Week High
32.20
52 Week High Date
Sep 25, 2018
52 Week Low
8.73
52 Week Low Date
Dec 26, 2018
52 Week Price Change
-14.92
52 Week Gain
-49.22%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 17. 2018
18.77
May 15. 2018
23.20
20 Trading Days
23.58%
Link
LONG
Jun 21. 2018
23.20
Jul 13. 2018
26.20
15 Trading Days
12.94%
Link
LONG
Aug 15. 2018
27.07
Sep 7. 2018
30.51
16 Trading Days
12.70%
Link
LONG
Jan 4. 2019
9.98
Jan 23. 2019
11.83
12 Trading Days
18.58%
Link
LONG
Apr 18. 2019
11.01
May 2. 2019
12.32
9 Trading Days
11.90%
Link
LONG
Jul 26. 2019
10.43
Aug 15. 2019
12.98
14 Trading Days
24.45%
Link
Company Information
Stock Symbol
CURO
Exchange
NASDAQ
Company URL
http://www.neuralstem.com
Company Phone
301-366-4841
CEO
Richard J. Daly
Headquarters
Maryland
Business Address
20271 GOLDENROD LANE, GERMANTOWN, MD 20876
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001357459
About

Description

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds. The company's stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical development products include NSI-189, which has completed Phase I clinical trial for the treatment of major depressive disorder, as well as is in Phase I clinical trial for the treatment of other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy; and NSI566 that has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. The company was founded in 1996 and is headquartered in Germantown, Maryland.